ata inclusion criteria
port year: 2015
ıntry: Denmark
Submission: ALL
use: ALL
netic status: ALL
mal Species: ALL
ecies grouping Level 1: ALL
ecies grouping Level 2: ALL
mmals: ALL
ting by Legislation: ALL
islative Requirement: ALL
n-human primates: ALL
omission Id: ALL
: ALL
: ALL

Narrative

ld 3: ALL

This report shows the number of uses of animals with the actual severity experienced by animals broken down by high-level purposes.


It also provides details of the actual severity for all sub-categories of purposes. Please see a listing and details of all categories of purposes in the Commission Implementing Decision 2012/707/EU

http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02012D0707-20140115

It shows both the first and all the subsequent uses of the animals completed in the reporting period (unless either aption is a period first and all the subsequent uses of the animals completed in the reporting period (unless either aption is a period first and all the subsequent uses of the animals completed in the reporting period (unless either aption is a period first and all the subsequent uses of the animals completed in the reporting period (unless either aption is a period first and all the subsequent uses of the animals completed in the reporting period (unless either aption is a period first and all the subsequent uses of the animals completed in the reporting period (unless either aption is a period first and all the subsequent uses of the animals completed in the reporting period (unless either aption is a period first and all the subsequent uses of the animals completed in the reporting period (unless either aption is a period first and all the subsequent uses of the animals completed in the reporting period (unless either aption is a period first and all the subsequent uses of the animals completed in the reporting period (unless either aption is a period first and all the subsequent uses of the animals completed in the reporting period (unless either approximately appr


_				
Dri	mary	/ DI	Irnc	COC
ги	IIIai v	v Du		

	Non-recovery	Mild [up to and including]	Moderate	Severe	Total uses
Basic Research	6,154	58,666	23,295	829	88,944
Translational and applied research	12,492	54,879	54,910	1,158	123,439
Regulatory use and Routine production	22	17,356	5,460	118	22,956
Protection of the natural environment in the interests of the health or welfare of human beings or animals		2,563	34	63	2,660
Preservation of species		258			258
Higher education or training for the acquisition, maintenance or improvement of vocational skills	2,588	3,352	211		6,151
Forensic enquiries					
Maintenance of colonies of established genetically altered animals, not used in other procedures		3			3
Total uses	21,256	137,077	83,910	2,168	244,411
%	8.70%	56.08%	34.33%	0.89%	




Basic research purposes

	Non-recovery	Mild [up to and including]	Moderate	Severe	Total uses
Oncology	50	2,688	3,026	109	5,873
Cardiovascular Blood and Lymphatic System	976	2,447	1,262	175	4,860
Nervous System	1,843	10,272	3,427	183	15,725
Respiratory System	27	387	843	5	1,262
Gastrointestinal System including Liver	91	1,467	948	33	2,539
Musculoskeletal System	8	2,524	146	4	2,682
Immune System	1,012	18,938	9,004	292	29,246
Urogenital/Reproductive System	189	1,541	873	20	2,623
Sensory Organs (skin, eyes and ears)	28	965	510		1,503
Endocrine System/Metabolism	1,282	10,420	859		12,561
Multisystemic	385	247	245	6	883
Ethology / Animal Behaviour /Animal Biology	32	3,852	1,040		4,924
Other basic research	231	2,918	1,112	2	4,263
Total uses	6,154	58,666	23,295	829	88,944
%	6.92%	65.96%	26.19%	0.93%	




Translational and applied research purposes

	Non-recovery	Mild [up to and including] M	loderate	Severe	Total uses
Human Cancer	2	5,975	3,116	22	9,115
Human Infectious Disorders	40	3,305	1,242	96	4,683
Human Cardiovascular Disorders	520	587	291	6	1,404
Human Nervous and Mental Disorders	2,471	13,061	19,934	102	35,568
Human Respiratory Disorders		22	51	2	75
Human Gastrointestinal Disorders including Liver	16	110	132		258
Human Musculoskeletal Disorders		241	157	2	400
Human Immune Disorders	1,348	6,406	2,226	57	10,037
Human Urogenital/Reproductive Disorders		63	3		66
Human Sensory Organ Disorders (skin, eyes and ears)	8	750	94		852
Human Endocrine/Metabolism Disorders	2,596	16,737	20,111	395	39,839
Other Human Disorders	5,471	1,590	1,841	235	9,137
Animal Diseases and Disorders	20	3,076	4,609	229	7,934
Animal Welfare		2,209	1,039		3,248
Diagnosis of diseases		663	8	11	682
Plant diseases					
Non-regulatory toxicology and ecotoxicology		84	56	1	141
Total uses	12,492	54,879	54,910	1,158	123,439
%	10.12%	44.46%	44.48%	0.94%	




Regulatory use and routine production purposes


	Non-recovery	Mild [up to and including]	Moderate	Severe	Total uses
Routine production	21				21
Quality control (incl batch safety and potency testing)	1	12,712	2,087	19	14,819
Other efficacy and tolerance testing		71	24		95
Toxicity and other safety testing including pharmacology		4,573	3,349	99	8,021
Total uses	22	17,356	5,460	118	22,956
%	0.10%	75.61%	23.78%	0.51%	



Quality control purposes						
		Mild [up to and including]	Moderate	Severe	Total uses	
Batch safety testing		3,570	114	3	3,687	
Pyrogenicity testing						
Batch potency testing	1	9,118	1,970	16	11,105	
Other quality controls		24	3		27	
Total uses	1	12,712	2,087	19	14,819	
%	0.01%	85.78%	14.08%	0.13%		

	Routine production purposes							
		Mild [up to and including]	Moderate	Severe	Total uses			
Blood based products	21				21			
Monoclonal antibodies								
Other product types								
Total uses	21				21			
%	100.00%							






Purpose

Toxicity and other safety testing by test type purposes


	Non-recovery	Mild [up to and including]	Moderate S	Severe	Total uses
Acute and sub-acute		41	663	82	786
Skin irritation/corrosion			12		12
Skin sensitisation			136	2	138
Eye irritation/corrosion		3	3		6
Repeated dose toxicity		882	859	14	1,755
Carcinogenicity					
Genotoxicity					
Reproductive toxicity					
Developmental toxicity					
Neurotoxicity					
Kinetics		438	1,656	1	2,095
Pharmaco-dynamics (incl safety pharmacology)		9			9
Phototoxicity					
Ecotoxicity		3,080			3,080
Safety testing in food and feed area					
Target animal safety		120			120
Other toxicity/safety testing			20		20
Total uses		4,573	3,349	99	8,021
%		57.01%	41.75%	1.23%	




Repeated dose toxicity purposes							
	Mild [up to and Non-recovery including] Moderate Severe						
up to 28 days		376	748	12	1,136		
29 - 90 days		457	29	2	488		
> 90 days		49	82		131		
Total uses		882	859	14	1,755		
%		50.26%	48.95%	0.80%			

Acute and sub-acu	e toxicity testing methods
-------------------	----------------------------

	Mild [up to and including]	Moderate	Severe	Total uses
LD50, LC50			80	80
Other lethal methods				
Non lethal methods	41	663	2	706
Total uses	41	663	82	786
%	5.22%	84.35%	10.43%	





Ecotoxicity purposes

	Non-recovery	Mild [up to and including]	Moderate	Severe	Total uses
Acute toxicity					
Chronic toxicity		3,080			3,080
Reproductive ecotoxicity					
Endocrine activity					
Bioaccumulation					
Other ecotoxicity					
Total uses		3,080			3,080
%		100.00%			

